About US
Contact us
-
Exclusive deal with Gilead on hep C to cut Massachusetts Medicaid costsFederal Medicaid officials lectured Gilead Sciences and other hep C drugmakers last year on the need to find ways to cut prices on their pricey meds for state Medicaid programs. Now, Massachusetts say2016/7/5
-
Arena chops 100-plus jobs as it shifts its priorities from struggling BelviqObesity med Belviq hasn’t been coming through for Arena ($ARNA)--and the drugmaker has seen enough. It’s changing up its priorities, but the move will cost 100 workers their jobs. The company is slas2016/7/4
-
Pfizer, Amgen most likely to bid for Medivation: analystsWith several Big Pharma players rumored to be interested in Medivation, plenty of industry watchers see another bidder potentially jumping into the mix to thwart Sanofi’s hostile quest. But which amon2016/7/4
-
GSK’s MenABCWY vaccine set to reshape meningococcal space, report saysAnticipated to grow to $1.8 billion by 2025, the global meningococcal vaccines market could see some big changes over the next decade. Pending successful late stage trials, GlaxoSmithKline’s forthcomi2016/7/1
-
Allergan's brand recognition, rebates keep aesthetics unit primed for growth: SpecialistsGood news for Allergan: The aesthetics market--which has lately been on the rise--is showing no signs of slowing down. At least, that’s the word from aesthetic specialists grilled by Leerink Partners2016/7/1
-
Pfizer to invest in new global biotechnology centre in ChinaAmerican-based pharmaceutical company Pfizer will invest nearly $350m to build a latest Global Biotechnology Centre in the Hangzhou Economic Development Area (HEDA), China. The modern HEDA facility i2016/6/30
-
Sanofi and Boehringer Ingelheim sign contract to $25bn business swapFrench drug maker Sanofi and German-based Boehringer Ingelheim have signed contracts in a bid to secure the strategic transaction that includes an exchange of Sanofi's animal health business Merial an2016/6/30
-
Should pharma scrap per-pill pricing completely?What if, instead of cutting drug prices, the pharma industry threw out the rulebook altogether? That’s just what a European trade group is proposing,Reutersreports, in a plan that would dump per-pill2016/6/29
-
Merck, Pfizer amp up ertugliflozin outcomes study as SGLT2 med scores in PhIIINEW ORLEANS--Merck & Co. and Pfizer are doubling down on their ertugliflozin cardiovascular outcomes study as rival SGLT2 med Jardiance continues to generate buzz for its recent score in a heart-s2016/6/29
-
Novo's weekly GLP-1 aces two head-to-head trials against Januvia, BydureonNEW ORLEANS--Novo Nordisk has staked out a big portion of its pipeline for semaglutide, the once-weekly GLP-1 drug that could follow in the footsteps of its blockbuster daily, Victoza. And this weeken2016/6/28